Clinical trials: Ipilimumab
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling…
- Trial name
- NCT07430202
- Testing
- DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
- Trial name
- NCT01673854
- Testing
- Ipilimumab, Vemurafenib
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Sarcoma, Wilm's Tumor
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
This study will examine the safety and efficacy of ipilimumab-an experimental cancer treatment drug used to boost immune response-in children, adolescents, and young adults.
- Conditions
- Sarcoma, Wilm's Tumor, Lymphoma, Neuroblastoma
- Trial name
- NCT01445379
- Testing
- Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
The purpose of this study is to test the side effects of an investigational vaccine with an immune booster, or 2 different boosters together.
- Trial name
- NCT01176474
- Testing
- NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057889
- Testing
- ipilimumab
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Malignant Melanoma Stage III
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
This is an international (Australia, Europe, and USA) open-label two-arm randomized phase 3 trial including 420 stage III (≤3 resectable in-transit metastases allowed) cutaneous or unknown primary melanoma patients.
- Trial name
- NADINA (NCT04949113)
- Testing
- Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 423 people
- Sponsor
- The Netherlands Cancer Institute
Cancer, Metastatic Cancer
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
The aim of this study is to assess the effectiveness of a battery of autoantibodies to predict the occurrence of immune-related adverse events (irAEs) in patients with cancer who will be treated with immune checkpoint inhibitors…
- Conditions
- Cancer, Metastatic Cancer, Solid Organ Cancer
- Trial name
- AUTENTIC (NCT03868046)
- Testing
- Treatment with immune checkpoint inhibitors., Blood tests.
- Where
- Spain
- Volunteers
- 242 people
- Sponsor
- Hospital Universitario Araba
Myocarditis, Cardiomyopathies
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) might induce high grade immune-related adverse events (irAEs) involving the cardio-vascular system.
- Conditions
- Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases
- Trial name
- JOCARDITE (NCT04294771)
- Testing
- ICI
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Colonic Neoplasms, Colorectal Neoplasms
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus [ChAd] and…
- Trial name
- NCT05456165
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 3 sites in United States
- Sponsor
- Gritstone bio, Inc.
Soft Tissue Sarcomas
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.
- Trial name
- NCT07444619
- Testing
- Pazopanib, Trabectedin, Ipilimumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Mesothelioma, Malignant
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
- Trial name
- NCT05324436
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Pan Tumor
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.
- Trial name
- CheckMate 848 (NCT03668119)
- Testing
- Nivolumab, Ipilimumab
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT07715565
- Testing
- Ipilimumab Injection, Sintilimab injection, Lenvatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- West China Hospital
Various Advanced Cancer
A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies.
- Trial name
- CheckMate 908 (NCT03130959)
- Testing
- Nivolumab, Ipilimumab
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 166 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma, Kidney Cancer
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world
- Trial name
- NCT03663946
- Testing
- Non-Interventional
- Where
- Japan
- Volunteers
- 81 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
This is an expanded access program (EAP) for participants who have progressed after prior systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor or mitogen-activated protein…
- Trial name
- NCT02083484
- Testing
- Pembrolizumab
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Skin
Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
Rationale: The randomized trial NADINA has demonstrated that neoadjuvant treatment with nivolumab with ipilimumab improves event-free survival (EFS) in patients with macroscopic resectable stage III melanoma.
- Trial name
- OMIT (NCT06754904)
- Testing
- Omitting TLND, Index node procedure
- Where
- Netherlands
- Volunteers
- 213 people
- Sponsor
- D.J. (Dirk) Grünhagen
Melanoma
Yervoy Pregnancy Surveillance Study
The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age
- Trial name
- NCT02854488
- Testing
- Yervoy
- Where
- United States
- Sponsor
- Bristol-Myers Squibb